Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia. Issue 5 (16th April 2021)

• Record Type: Journal Article
• Authors: Ning, Liqing; Li, Dengju; Lu, Pingfan; Que, Yimei
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 5(2021)
• Page Start: 1211
• Page End: 1218
• Publication Date: 2021-04-16
• Subjects: Acute myeloid leukemia -- hospital costs -- hospital stay -- induction therapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1855339
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The financial burden of acute myeloid leukemia (AML) patients is substantial. We retrospectively analyzed the hospital costs of the first induction therapy for 353 newly diagnosed AML patients who were admitted to our hospital from January 2013 to December 2018. We found the median hospital costs were estimated at 110, 291.8 RMB. Multivariate analysis showed that length of hospital stay was the leading determinant affecting hospital costs ( p < 0.0001), followed by length of agranulocytosis days ( p < 0.01), but for the patients who failed to achieve complete remission (CR), length of hospital stay was the independent factor contributing to hospital costs. Besides, patients achieving CR had similar hospital costs to the patients failing to achieve CR. The hospital costs of low-intensity chemotherapy might not be lower than that of intensive chemotherapy.